Navigation Links
Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
Date:7/18/2011

CAMBRIDGE, England, July 19, 2011 /PRNewswire/ --


Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announces that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started.

LSR is a common neuropathic pain condition caused by compression of the nerve roots in the lumbar region of the spine. Common features include pain radiating from the lower back down the legs, together with sensory and motor impairment in the lower limbs. LSR is a very high unmet medical need, affecting 3-5% of the global population and there are no drug treatments currently approved for treating this type of neuropathic pain.[1]

The Phase II trial is a randomised, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of orally administered CNV1014802 in patients with pain associated with LSR. It is an innovative study, incorporating a number of design features which will enhance confidence in the outcome of the study. The trial will run in four European countries and results are expected in the second half of 2012.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, added: "We are delighted to announce the start of this trial; the second clinical stage trial initiated since our conception as a Company in October 2011 and a testament to our innovative team. It is clear that safe, effective pain treatment is urgently required and we are focussed on driving forward the development of our pipeline to meet this need."

Commenting on the announcement, Simon Tate, Chief Scientific Officer of Convergence Pharmaceuticals, said: "We are very excited to be initiating this Phase II study for CNV1014802.  CNV1014802's differentiated and superior profile could have a significant impact on the treatment of patients with
'/>"/>

SOURCE Convergence Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
4. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
7. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
8. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., ... has filed a Clinical Trial Application (CTA) with the ... Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical ... Anatabine Citrate. Contingent on the Company receiving ... Phase I trial to assess the safety, tolerability and ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy ... that it has signed a letter of intent ... has developed and patented a nanotechnology-based development platform ... products that enable rapid on-site collection and testing ... and health issues in an immediate, non-invasive and ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... 19, 2014  Roche (SIX: RO, ROG; OTCQX: RHHBY) ... (Bina), a privately held company based in ... provides a big data platform for centralized management ... Bina,s proprietary on-market Genomic Management Solution, Bina-GMS 1 ... perform fast and scalable analyses to maximize the ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... SPRING, Md., Aug. 24, 2011 United Therapeutics ... the completion of its FREEDOM-C(2) Phase 3 trial ... release oral formulation of treprostinil, a stable synthetic ... hypertension (PAH).  Preliminary analysis demonstrates that the trial ...
... the Trudeau Institute may help to explain why live ... protection. The research is published in this month,s ... entitled "Live attenuated influenza vaccine (LAIV) impacts innate and ... scientist Dr. Laura Haynes and her colleagues. "Our ...
... ANN ARBOR, Mich.---A delicate balance of atomic forces can ... in size---an attribute that,s important for many nanotech applications ... The same type of forces are at ... the inorganic supercluster structures in this research are in ...
Cached Biology Technology:FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 4Trudeau Institute announces a discovery in how FluMist elicits protection 2Engineers discover nanoscale balancing act that mirrors forces at work in living systems 2
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that ... and at least seven more will participate in the upcoming ... Hotel in Washington D.C. , Dec. 2-4. ... support from the regulatory agencies in the United ... our effort to help advance the use of metrics in ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... 2013, Shenzhen, China-The China National Genebank (CNGB) announces ... Project (Fish T1K), a groundbreaking transcriptome study designed ... and diversification of the largest group of vertebrates. ... approaches and strategies to address challenges in fish ...
... 650 years of annual change in sea-ice cover can been ... says a new study from the University of Toronto Mississauga ... have been used to track changes in Arctic sea ice," ... Chemical and Physical Sciences. "We found the algal record shows ...
... City, November 18, 2013 Ph.D. student Karita ... Environnement Research Centre, in collaboration with other Canadian, ... emissions produced by thawing permafrost in the Canadian ... climate models. Their findings, published in the journal ...
Cached Biology News:China National Genebank initiates collaboration to sequence transcriptomes of 1,000 fish species 2Underwater 'tree rings' 2Global warming in the Canadian Arctic 2
Chaperone Sampler Kit 10 mu g each...
Zonula Adherens Sampler Kit 10 mu g each...
Tumor Suppressor Sampler Kit 10 mu g each...
Umbilical cord blood eosinophils, For immunohistochemistry (IHC)...
Biology Products: